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a  b  s  t  r  a  c  t
To  determine  if oxidative  stress  and  inflammation  are  linked  with  major  depressive  disorder,  nicotine
dependence  and  both  disorders  combined.  This  study  comprised  150 smokers  and  191 never  smokers.  The
instruments  were:  a socio-demographic  questionnaire,  diagnoses  of mood  disorder  and  nicotine  depend-
ence according  to  DSM-IV,  (SCID-IV),  and  the  Alcohol,  Smoking  and  Substance  Involvement  Screening
Test.  Laboratory  assessments  included:  nitric  oxide  metabolites  (NOx),  lipid  hydroperoxides,  malondi-
aldehyde  (MDA),  total  reactive  antioxidant  potential  (TRAP),  advanced  oxidation  protein  products  (AOPP),
fibrinogen  concentrations,  homocysteine,  erythrocytes  sedimentation  rate  (ESR)  and  high-sensitivity  C-
reactive  protein  (hs-CRP)  were  assayed  from  blood  specimens.  Statistically  significant  differences  were
found among  depressed  smokers  who  had  more  severe  depressive  symptoms,  a  higher risk  of alcohol
consumption,  more  suicide  attempts,  and  more  disability  for  work  than  non-depressed  never  smokers.
Depressed  smokers  had  significantly  higher  levels  of  NOx,  fibrinogen,  hs-CRP,  AOPP,  ESR  and  lower  levels
of TRAP  compared  to  non-depressed  never  smokers.  Depressed  smokers  had  significant  levels  of oxida-
tive stress  and  inflammatory  biomarkers  after  adjusting  for gender,  age,  years  of education,  disability  for
work,  and  laboratory  measures.  The  levels  of  NOx,  lipid  hydroperoxides,  AOPP,  and  fibrinogen  were  sub-
stantially  higher,  whereas  levels  of TRAP  were  lower  in depressed  smokers  compared  to non-depressed
never  smokers.  (1)  Depressed  smokers  exhibited  altered  concentrations  of NOx,  lipid  hydroperoxides,
AOPP,  TRAP,  and  fibrinogen.  (2) Depressed  smokers  were  more  unable  to work,  showed  more  severe
depressive  symptoms  and  attempted  suicide  more  frequently.
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1. Introduction35
Tobacco use is a risk factor for disability and morbidity, as well36
as the most preventable cause of death in the world [32]. Smokers37
more often presented with impaired work/domestic functionality,38
more frequent hospitalization, more depressive disorders, more39
sedative use and a family history of mental disorders, as well as40
scoring lower on the quality of life scale compared with never41
smokers [6].  Smoking with nicotine dependence increases the risk42
of developing major depressive disorders [25], contributes to more43
severe depressive symptoms [3,14] and is associated with suicidal44
behavior [4,20].45
Major depressive disorder is accompanied by an increase in46
oxidative stress and a decrease in antioxidant status, which dam-47
ages neurons and has an important role in the pathophysiology48
of depressive disorders [2,10,17,19,22].  There is also data link-49
ing oxidative stress and nicotine dependence [28]. Oxidative and50
nitrosative stress and inflammation induced damage to fatty acids,51
proteins, DNA, mitochondria and consequent autoimmune reac-52
tions, which link to neuroprogression and degenerative processes53
that occur in depressive disorders [2,19].  Nitric oxide plasma con-54
centration is associated with cognitive impairment in patients with55
recurrent depressive disorders [29]. These alterations may  lead56
brain damage, which may  be a pathway to neurodegenerative dis-57
eases [13], as well as neuroprogression of mood disorders [2,19].58
The purpose of this study was to elucidate the involvement59
of oxidative and nitrosative stress and inflammatory markers,60
including nitric oxide metabolites (NOx), lipid hydroperoxides,61
malondialdehyde (MDA) advanced oxidation protein products62
(AOPP), total reactive antioxidant potential (TRAP) and inflam-63
matory biomarkers (high-sensitivity C-reactive protein (hs-CRP),64
fibrinogen, homocysteine, erythrocytes sedimentation rate (ESR))65
in depressed and non-depressed smokers compared to depressed66
and non-depressed never smokers. We  also hypothesized that67
depressive smokers would have co-occurring disorders such as68
more risk of alcohol use, more suicide attempts, more physical dis-69
eases, more severe symptoms, as well as more disability for work70
than non-depressed never smokers.71
2. Materials and methods72
2.1. Study population73
Smokers (n = 150) were recruited from outpatients at the Cen-74
tre of Approach and Treatment for Smokers, at Londrina State75
University (UEL), Paraná, Brazil and never smokers (n = 191) were76
recruited from staff of UEL. The sample size calculation of was based77
on smokers and never smokers with and without depression. The78
study sample size calculation showed that a sample of 34 never79
smokers and 27 smokers (total n = 61) would be able to detect a80
59% prevalence of depressive disorders among smokers compared81
to 17% depressive disorders among non-smokers (odds ratio = 7.03)82
with a confidence level of 0.95 and 95% power. It was assumed83
that the ratio of control to case was 1.27. However we are able to84
recruit 191 never smokers and 150 smokers and that sample size85
would be adequately powered to detect population level preva-86
lence of depressive disorders among smokers and never smokers87
as reported in the literature [6,7].88
Smokers and never smokers were men  and women aged 18–6089
and all ethnicities were accepted for this study. The study was con-90
ducted from March 2011 to July 2012.91
Exclusion criteria were presence of medical comorbidities92
including chronic obstructive pulmonary disease, rheumatoid93
arthritis, systemic lupus erythematosus, inflammatory bowel dis-94
ease, HIV infection, neurodegenerative and neuroinflammatory95
disorders, such as Alzheimer’s, Huntington’s and Parkinson’s disor- 96
der, multiple sclerosis and stroke, conditions such as hemodialysis, 97
use of interferon. All these conditions are known to share periph- 98
eral inflammation and cell-mediated immune activation [17]. All 99
study participants needed to have normal blood values on the fol- 100
lowing laboratory tests: hemogram, aspartate transaminase (AST), 101
alanine transaminase (ALT), urea, and creatinine. 102
All subjects had given written informed consent to participate in 103
the study after the approval of this research by the Ethics Research 104
Committee at Londrina State University (UEL), number 250/2010. 105
2.2. Instruments 106
2.2.1. Questionnaire 107
A self-reported questionnaire was used to gather information 108
on socio-demographic, clinical characteristics and smoking status. 109
2.2.2. Major depressive disorder and nicotine dependence 110
The diagnoses of major depressive disorder and nicotine 111
dependence were made at interview by a trained clinician using 112
DSM-IV, criteria translated and validated into Portuguese [8]. 113
2.2.3. Hamilton Depression Rating Scale 114
A translated and validated version of the Hamilton Depres- 115
sion Rating Scale, adapted to the Brazilian cultural context and 116
Portuguese language [21] was used to measure the severity of 117
depression in study participants who  had been diagnosed with 118
major depressive disorder. 119
2.2.4. The Alcohol, Smoking and Substance Involvement 120
Screening Test (ASSIST) 121
The World Health Organization (WHO) developed Alcohol, 122
Smoking and Substance Involvement Screening Test (ASSIST) is a 123
questionnaire to screen for levels of risk for alcohol, smoking and 124
substance use in adults. ASSIST scores were calculated for all par- 125
ticipants. A risk score for alcohol was  calculated as low risk (score 126
0–3), moderate risk (score 4–26) or high risk (score ≥27) [31]. 127
2.3. Laboratory assessments 128
Peripheral blood samples were collected from all participants 129
after 12–14 h overnight fasting. Lipid hydroperoxides were mea- 130
sured by the ferrous oxidation of xylenol assay using an adaptation 131
of the technique described by Jiang [16]. The levels of nitric oxide 132
metabolites (NOx) were assessed by measuring the plasma concen- 133
tration of nitrite and nitrate, using an adaptation of the technique 134
described by Navarro-Gonzálvez et al. [23]. TRAP was  measured by 135
chemiluminescence in an adaptation of the method described by 136
Repetto et al. [27]. The quantification of advanced oxidation protein 137
products (AOPP) in plasma used the method described by Witko- 138
Sarsat et al. [30]. Malondialdehyde (MDA) is a secondary product of 139
lipid peroxidation and was determined using the method described 140
by Jentzch et al. [15]. 141
We  measured the serum concentration of hs-CRP by 142
immunonephelometry system on a BNII analyzer (Siemens® 143
System BNTMII, Deerfield, IL, USA). ESR was performed by an 144
automatic analyzer for erythrocyte sedimentation rate determi- 145
nation (MicroTest1X – Sire Analytical Systems, Udine, Italy). The 146
quantitative determination of fibrinogen in plasma was  based on 147
the Clauss method. This method measures the rate of fibrinogen to 148
fibrin conversion in the presence of excess thrombin. This method 149
was performed by a coagulation analyser (Destiny Plus – Trinity 150
Biotech GmbH, Lemgo, Germany). The determination of serum 151
homocysteine was performed on an ARCHITECT i System (Abbot, 152
Wiesbaden, Germany).
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Table 1
Demographic and clinical characteristics by smoking and depressive disorder.
Characteristics Never-smoker Smoker p-Valuea
Non-depressed (n = 123) Depressed (n = 68) Non-depressed (n = 78) Depressed (n = 72)
n % n % n % n %
Gender 0.008
Male  47 (38.2) 14 (20.6)* 35 (44.9) 20 (27.8)
Female 76 (61.8) 54 (79.4)* 43 (55.1) 52 (72.2)
Age 0.079
18–29 6 (4.9) 1 (1.5) 4 (5.1) 6 (8.3)
30–39 18 (14.6) 8 (11.8) 8 (10.3) 12 (16.7)
40–49 63 (51.2) 38 (55.9) 29 (37.2) 25 (34.7)*
50–60 36 (29.2) 21 (30.9) 37 (47.4)** 29 (40.3)
Ethnicity 0.524
Caucasian 84 (68.3) 48 (70.6) 53 (67.9) 48 (66.7)
African 14 (11.4) 5 (7.4) 8 (10.3) 9 (12.5)
Asian 9 (7.3) 3 (4.4) 4 (5.1) 0 (.0)*
Mixed 16 (13.0) 12 (17.6) 13 (16.7) 15 (20.8)
Marital status 0.289
Stable  relationship 85 (69.1) 48 (70.6) 52 (66.7) 40 (55.6)
Years of education 0.000
≤12  years 28 (22.8) 9 (13.2) 58 (74.4)** 51 (70.8)**
≥13 years 94 (76.4) 55 (80.9) 19 (24.4)** 18 (25.0)**
Disability for work 0.000
Yes 2 (1.6) 1 (1.5) 14 (17.9)** 19 (26.4)**
Suicide attempt
Yes 0 (.0) 2 (2.9) 2 (2.6) 22 (30.6)** 0.000
Hamilton scale (mean, SD)
Yes 1.6 (2.3) 6.9 (7.9) 4.5 (4.6) 14.4 (9.4)** 0.000
Alcohol ASSIST
Yes 1 (.8) 1 (1.5) 8 (10.3)** 16 (22.2)** 0.000
a The p-value tests based on Pearson Chi-square test. The Hamilton scale based Kruskal–Wallis test, other characteristics it is based on the Pearson Chi-square test.
* p = 0.05.
** p = 0.01.
2.4. Statistical analyses153
Analyses were performed examining the relationship between154
the non-depressed never-smoker with depressed smokers, non-155
depressed smokers and depressed never smokers. Comparisons156
were made between these for socio-demographic, clinical and lab-157
oratory measurements, using appropriate parametric tests where158
data were normally distributed and non-parametric statistical tests159
for categorical or non-normal data. All tests were 2-tailed and a160
p-value of 0.05 was used for statistical significance.161
Univariate comparisons were initially conducted and then162
variables that were statistically significant were included in the163
multivariate analyses. A generalized multinomial regression anal-164
ysis was carried out using non-depressed never-smoker, depressed165
never-smoker, non-depressed smoker and depressed smoker cat-166
egories as the dependent variable. The multinomial regression167
analysis was used to estimate the odds that depressed never-168
smokers, non-depressed smokers or depressed smokers, compared169
with non-depressed never-smokers, was associated with each of170
the independent variables. All analyses were performed using SPSS171
(Version 20).172
3. Results173
In examining socio-demographic and clinical variables, smoking174
and depressive status did not differ with respect to marital sta-175
tus, age and ethnicity. The depressed and non-depressed smokers176
were significantly different in having fewer years of education and177
more disability for work compared to non-depressed never smok-178
ers (p < 0.01). Depressed smokers had significantly more disability179
for work than non-depressed never smokers (p < 0.01). The mean180
age for all groups was 46.25 years (Table 1).181
Depressed smokers showed statistically significant differ-182
ences in consuming more alcohol, requiring more frequent183
hospitalization, attempting suicide more frequently, and being 184
more unable to work than non-depressed never smokers. The 185
depressed smokers also exhibited significant differences in severity 186
of depression (higher Hamilton scores) compared with depressed 187
never smokers (Table 1). 188
Depressed smokers had significantly higher levels of oxidative 189
stress (NOx, AOPP) and lower levels of antioxidants (TRAP), higher 190
levels of inflammatory biomarkers (fibrinogen, hs-CRP, ESR) com- 191
pared to non-depressed never smokers However, smokers from all 192
groups did not differ with respect to levels of homocysteine, lipid 193
hydroperoxides and MDA  (Table 2). 194
These results did not change when we analyzed these vari- 195
ables using multinomial regression analysis after adjusting for 196
gender, age, years of education, disability for work, and labora- 197
tory measures. We  found the levels of NOx, AOPP (OR = 1.02, 95% 198
CI = 1.01–1.03), and fibrinogen were substantially higher, and lev- 199
els of TRAP were lower (OR = 0.99, 95% CI = 0.99–1)  in depressed 200
smokers compared to non-depressed never smokers. However, the 201
association between hs-CRP and ESR in depressed smokers was 202
no longer significant after the multinomial regression analysis. On 203
the other hand, we found significant differences in levels of lipid 204
hydroperoxides (OR = 3.14, 95% CI = 1.25–7.88) (Table 3). 205
Using multinomial regression analysis, depressed never 206
smokers comprised more women  (odds ratio was 4.06, 95% 207
CI = 1.58–10.43) compared to non-depressed never smokers. 208
Depressed smokers were more unable to work (OR = 7.85, 95% 209
CI = 1.29–47.90) compared to non-depressed never smokers. 210
4. Discussion 211
The current study demonstrated that depressed smokers had 212
significantly higher levels of oxidative stress such as raised 213
NOx (products of nitrates and nitrites), lipid hydroperoxides (a 214
biomarker of oxidative damage to lipids), AOPP (a biomarker 215
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Table 2
Comparison of laboratory measurements of oxidative stress and inflammatory biomarkers by smoking status and/or depressive disorder.
Laboratory measures Never-smoker Smoker p-Valuea
Non-depressed Depressed Non-depressed Depressed
Mean SD Mean SD Mean SD Mean SD
CRP 2.8 (4.1) 2.5 (3.4) 4.1 (4.7)** 4.1 (4.7)** 0.000
NOx  3.3 (1.8) 3.3 (2.1) 5.3 (2.7)** 4.5 (2.1)** 0.000
Lipid  hydroperoxides 0.9 (.4) 0.9 (.4) 1.0 (.4) 1.1 (.6)* 0.125
AOPP 98.5 (38.6) 103.5 (41.8) 109.9 (46.9)** 117.3 (48.0)** 0.018
TRAP 838.3 (131.7) 830.7 (135.3) 836.0 (142.5) 780.1 (126.8)** 0.020
MDA 16.0  (5.4) 14.8 (5.4) 16.0 (5.4) 16.4 (7.1) 0.501
Fibrinogen 327.9 (66.2) 323.4 (62.1) 368.1 (73.8)** 365.6 (67.9)** 0.000
ERS  12.3 (10.8) 11.5 (9.1) 14.6 (10.5) 17.8 (14.3)* 0.015
a The p-value for all the laboratory measurements except TRAP is based on the independent samples Kruskal–Wallis test and for TRAP it is based on the oneway ANOVA.
* Significance at the 0.05 level.
** Significance at the 0.01 level and the comparison is between the non-depressed never-smokers and the other three groups based on the Mann–Whitney U test for all
variables except TRAP and for TRAP it is based on the independent sample t-test.
of oxidative damage to proteins) and lower levels of TRAP (a216
biomarker of anti-oxidants) than non-depressed never smokers.217
In depressed smokers we also found differences in inflammatory218
biomarkers such as fibrinogen compared to non-depressed never219
smokers. Furthermore, non-depressed and depressed smokers had220
significantly higher levels of NOx and fibrinogen compared to221
non-depressed never smokers. Our results were consistent with222
previous studies which have examined markers of oxidative stress223
disturbances in patients with depression, but which did not con-224
sider comorbid nicotine dependence [10,29].  Our study included225
depressed smokers with nicotine dependence.226
This study provides evidence for an association between227
depressed smokers and higher levels of AOPP, a measure of oxi-228
dation damage to proteins [1].  AOPP correspond to highly oxidized229
proteins and specifically to albumin and might be formed during230
oxidative stress by reaction of plasma proteins with chlorinated231
oxidants. Thus, AOPP have been considered as a novel marker of232
oxidant-mediated protein damage [1].233
Patients with both major depression and nicotine dependence234
also had higher levels of lipid hydroperoxides, a marker of oxidative235
damage. Consistent with previous research that found higher lev-236
els of serum F2a-isoprostanes (8-iso-PGF2a), we found high levels237
of lipid hydroperoxides, a biomarker of oxidative damage to lipids,238
in depressed compared to non-depressed individuals [33]. Further-239
more, depressive smokers had significantly lower concentrations of240
TRAP, a measure of global antioxidant defenses. Cigarette smoking241
and depression are significant factors in alterations of the oxi-242
dant and antioxidant balance in blood, resulting in potentoxidative243
stress and in these conditions a lipoperoxidation process can occur 244
[5,19]. 245
In our study, fibrinogen concentrations were higher in smokers 246
with and without depression compared to non-depressed never 247
smokers. These findings are in accordance with other research 248
that has found strong associations between fibrinogen, persistent 249
depressive symptoms and smoking [12]. Fibrinogens and hs-CRP 250
are inflammatory biomarkers. Thus, cigarette smoking and depres- 251
sive disorders may  increase the levels of inflammatory biomarkers 252
and the production of oxidants, and may  decrease the levels of 253
antioxidants. An increase in inflammation and oxidative stress is 254
documented in mood disorders [2,19].  There is also data linking 255
oxidative stress and inflammation in cigarette smoking and lung 256
disease [28]. 257
Higher levels of CRP were consistently associated with depres- 258
sive disorder, and remained significant after controlling for gender, 259
age, smoking status, physical activity weight, as well as medication 260
use and medical conditions potentially influencing inflammation 261
levels [9,18,25]. Furthermore, in univariate analyses, there were 262
higher levels of CRP in smokers with and without depression than 263
non-depressed never smokers. However, in multinomial analysis 264
our data did not suggest that the highest levels of CRP were a 265
consequence of smoking or depressive disorder. 266
Our study found an association between higher levels of NOx 267
and smokers with and without depression compared with non- 268
depressed never smokers. Higher concentration of plasma NOx in 269
patients with recurrent depressive disorder was associated with 270
the severity of depressive symptom and cognitive impairment, 271
Table 3
Multinomial regression analysis of variables associated with smoking and/or depression.






ORb 95% CI p-Value ORb 95% CI p-Value ORb 95% CI p-Value
Femalea 4.06 (1.58–10.43) 0.00** 0.84 (0.34–2.08) 0.70 1.48 (0.55–3.98) 0.44
Age  1.02 (0.98–1.07) 0.29 1.02 (0.98–1.07) 0.30 0.99 (0.95–1.04) 0.74
Years  of education 1.03 (0.96–1.12) 0.40 0.78 (0.72–0.86) 0.00** 0.82 (0.75–0.90) 0.00**
Disability for work,a yes 0.60 (0.04–8.32) 0.70 5.17 (0.86–30.99) 0.07 7.85 (1.29–47.9) 0.03*
CRP 0.98 (0.88–1.09) 0.72 0.94 (0.85–1.04) 0.25 0.93 (0.83–1.03) 0.16
NOx  1.03 (0.85–1.25) 0.75 1.45 (1.21–1.75) 0.00** 1.28 (1.05–1.57) 0.02*
Lipid hydroperoxides 1.56 (0.65–3.71) 0.32 1.41 (0.56–3.52) 0.47 3.14 (1.25–7.88) 0.01*
AOPP 1.01 (1.00–1.02) 0.15 1.01 (1.00–1.02) 0.10 1.02 (1.01–1.03) 0.00**
TRAP 1.00 (1.00–1.00) 0.56 1.00 (0.99–1.00) 0.07 0.99 (0.99–1.00) 0.00**
Fibrinogen 1.00 (0.99–1.01) 0.63 1.01 (1.01–1.02) 0.00** 1.01 (1.01–1.02) 0.00**
ERS 0.96 (0.92–1.01) 0.11 0.96 (0.92–1.00) 0.07 0.97 (0.93–1.01) 0.18
a Reference categories: gender, male; disability for work, no.
b Odds ratios (OR) mutually adjusted for each of the presented variables.
* p = 0.05.
** p = 0.01.
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suggesting that an overproduction of nitric oxide via inducible272
nitric oxide synthase, inducible nitric oxide synthase (iNOS), which273
results in oxidative stress and cell damage [29]. Increased produc-274
tion of NO and peroxynitrite may  cause nitration and nitrosylation275
of proteins that appears related to the pathogenesis of depression276
[22]. Induction of nitric oxide leads to an activation of nuclear factor277
kappa B (NF-B), which is relevant to the development of depres-278
sive disorders [26].279
Depressive smokers were more unable to work, showed more280
severe depressive symptoms and attempted suicide more fre-281
quently compared with non-depressed never smokers. Our data282
are consistent with previous reports that have shown that current283
smoking is associated with subsequent suicidal behavior [4] and284
more disability for work and more hospitalization [7,24].285
The results of this study should be interpreted with regard to286
its strengths and limitations. The present study design was a cross-287
sectional study, which can only examine an exposure at a particular288
time, but cannot determine causal relationships [11]. In our study,289
the never smokers were highly educated; this could generally lead290
to healthy behavior patterns.291
Despite of some limitations, our findings provide evidence of a292
link between depressed smokers and altered oxidative stress and293
inflammatory marker. In addition, our data suggest that depressed294
smokers were more unable to work, showed more severe depres-295
sive symptoms and attempted suicide more frequently.296
5. Conclusion297
Our results corroborate the inflammatory, oxidative and298
nitrosative stress theory of depression, and suggest that inflam-299
matory, oxidative and nitrosative stress could be worsened by300
concomitant nicotine dependences. Depressed smokers exhibited301
altered concentrations of NOx, lipid hydroperoxides, AOPP, TRAP,302
and fibrinogen. Depressive smokers were more unable to work,303
showed more severe depressive symptoms and attempted suicide304
more frequently.305
These findings need further studies to better understand the role306
of shared inflammatory, oxidative and nitrosative stress pathways307
in depressive disorders and nicotine dependence, which impacts308
on the course and severity of both diseases. The translational309
implications of these findings include the opportunity to iden-310
tify subgroups of major depressive disorder with comorbidity with311
nicotine dependence, to potentially protect them from the effects312
of oxidants by applying new therapies.313
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